FDA Aligns With Rocket Pharmaceuticals on 12-Patient Pivotal Phase 2 Design for Danon Disease Gene Therapy RP-A501
核心洞察
The FDA confirmed a 12-patient pivotal efficacy population for RP-A501 in Danon disease (搜索), with the first three patients treated under the modified protocol counting toward that total.
Rocket Pharmaceuticals must enroll and dose nine additional male patients at the recalibrated dose of 3.8 x 10^13 genome copies per kilogram using commercial-grade product.
The trial retains 12-month co-primary endpoints of myocardial LAMP2 (搜索) protein expression and a 10% reduction in left ventricular mass index, intended to support accelerated approval.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced alignment with the U.S. Food and Drug Administration on continued enrollment and dosing and key elements of the global pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease (搜索), including the recalibrated dose, a 12-patient pivotal population and the established 12-month co-primary endpoints. The company's shares gained as much as 8% in early trading Tuesday following the disclosure, before paring some of the initial surge to trade up roughly 5% in the opening session.
Pivotal Population and Dosing
The FDA confirmed that the pivotal study population will comprise 12 male patients treated with RP-A501 at the recalibrated dose of 3.8 × 10¹³ genome copies per kilogram (GC/kg) using commercial-grade product. The first three patients treated at the recalibrated dose under the modified protocol count toward the 12-patient pivotal population, leaving nine additional patients to be enrolled and treated. Rocket expects to complete dosing of the remaining patients by mid-2027.
The agency's review of available safety data included results from those first three patients. All three completed at least four weeks of follow-up and had been discharged following protocol-specified observation. No clinical or laboratory evidence of thrombotic microangiopathy or capillary leak syndrome had been observed. Following its review, the FDA confirmed continued enrollment and dosing under the modified protocol at the recalibrated dose.
"FDA's confirmation of the pivotal efficacy framework marks an important milestone for RP-A501 and the Danon disease (搜索) community," said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals. "With the first three patients counting toward the 12-patient pivotal population and the established co-primary endpoints preserved, we now have a clear and actionable path to complete the pivotal study. The initial clinical experience at the recalibrated dose and supportive product-bridging data further reinforce the path forward."
Endpoints and Accelerated Approval Path
The primary assessment will occur at 12 months using the previously established co-primary endpoints of myocardial LAMP2 (搜索) protein expression and a 10% reduction from baseline in left ventricular mass index. These endpoints are intended to support a potential accelerated approval pathway.
The modified protocol incorporates the recalibrated RP-A501 dose and an optimized immunomodulatory regimen comprised of rituximab, sirolimus and corticosteroids, together with enhanced eligibility criteria, safety monitoring and risk-mitigation measures. The recalibrated dose was selected based on analytical characterization of the Phase 2 commercial-grade product, including its full-particle content, and is supported by nonclinical bridging data.
Nonclinical Bridging Data
Nonclinical bridging data further support the pharmacologic activity of the recalibrated dose. In a Danon disease (搜索) mouse model, administration of Phase 2 material at 3.8 × 10¹³ GC/kg resulted in cardiac LAMP2B protein expression comparable to that observed at a higher dose and demonstrated comparable vector biodistribution.
Disease Context and Program Outlook
Danon disease (搜索) is a rare genetic condition caused by mutations in the LAMP2 (搜索) gene, leading to severe cardiomyopathy that predominantly affects males and often proves fatal by early adulthood. There are currently no approved disease-modifying therapies for the condition.
Rocket plans to provide a comprehensive update on the Danon disease (搜索) program during a virtual investor webinar on Tuesday, October 6, 2026, at 4:30 p.m. ET, with additional information, including webcast access details, to be available in the Investors section of the company's website. The FDA alignment follows a period of uncertainty for the program after Rocket revised its dosing and immunomodulatory protocol; the confirmation that already-treated patients will count toward the pivotal efficacy population effectively shortens the clinical timeline and reduces the cost of completing the trial.
Rocket Pharmaceuticals is a fully integrated, commercial-stage biotechnology company developing genetic medicines for rare and life-threatening diseases, with a strategic focus on inherited cardiovascular disorders and additional programs in hematology and immunology. Its cardiovascular portfolio includes three clinical-stage gene therapy programs targeting hypertrophic, arrhythmogenic and dilated cardiomyopathies. The company's integrated platform combines proprietary adeno-associated virus (AAV) manufacturing capabilities, clinical experience in cardiac gene therapy, and long-term safety and efficacy data supporting advancement across its cardiovascular portfolio. According to a summary of the company's presentation at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, early data in PKP2 (搜索) and BAG3 (搜索) programs showed promising efficacy and safety, and strong cash reserves support ongoing trials.